8 results match your criteria: "The James Comprehensive Cancer Center at The Ohio State University[Affiliation]"

Article Synopsis
  • - Malignant struma ovarii is a very rare type of tumor with limited guidelines for treatment and monitoring, mainly based on past case studies and data.
  • - Some researchers suggest classifying this condition into low-risk and high-risk categories, with careful management for those considered low-risk.
  • - The text discusses a unique case where a patient with initially low-risk malignant struma ovarii experienced a recurrence of metastatic disease despite following surveillance protocols.
View Article and Find Full Text PDF

Purpose: The role of stereotactic radiosurgery (SRS) in the management of grade 2 and 3 meningiomas is not well elucidated. Unfortunately, local recurrence rates are high, and guidelines for management of recurrent disease are lacking. To address this knowledge gap, we conducted STORM (Salvage Stereotactic Radiosurgery for Recurrent WHO Grade 2 and 3 Meningiomas), a multicenter retrospective cohort study of patients treated with primary SRS for recurrent grade 2 and 3 meningiomas.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the outcomes of stereotactic radiosurgery (SRS) for small-cell lung cancer (SCLC) brain metastases compared to non-small cell lung cancer (NSCLC), addressing historical concerns about SCLC's prognosis and neurological risks.
  • Data from multiple centers and a clinical trial were analyzed, focusing on overall survival (OS) and central nervous system (CNS) progression for patients with SCLC and NSCLC over a 22-year period.
  • Results indicated that patients with NSCLC experienced better overall survival compared to those with SCLC, with significant differences in survival and CNS progression rates across various analyses, particularly favoring NSCLC cases.
View Article and Find Full Text PDF

Targetable Intercellular Signaling Pathways Facilitate Lung Colonization in Osteosarcoma.

Adv Exp Med Biol

December 2020

Division of Hematology, Oncology, and Blood and Marrow Transplant, Department of Pediatrics, Center for Childhood Cancer and Blood Diseases, Abigail Wexner Research Institute at Nationwide Children's Hospital and The James Comprehensive Cancer Center at The Ohio State University, Columbus, OH, USA.

Outcomes for young people diagnosed with osteosarcoma hinge almost exclusively on whether they develop lung metastasis. The striking predilection that osteosarcoma shows for metastatic spread to lung suggests properties and/or lung interactions that generate tissue-specific survival and proliferation advantages. While these mechanisms remain overall poorly defined, studies have begun to describe biological elements important to metastasis.

View Article and Find Full Text PDF

Understanding and Modeling Metastasis Biology to Improve Therapeutic Strategies for Combating Osteosarcoma Progression.

Front Oncol

January 2020

Poul Sorensen Laboratory, Department of Molecular Oncology, BC Cancer, Part of the Provincial Health Services Authority in British Columbia, Vancouver, BC, Canada.

Osteosarcoma is a malignant primary tumor of bone, arising from transformed progenitor cells with osteoblastic differentiation and osteoid production. While categorized as a rare tumor, most patients diagnosed with osteosarcoma are adolescents in their second decade of life and underscores the potential for life changing consequences in this vulnerable population. In the setting of localized disease, conventional treatment for osteosarcoma affords a cure rate approaching 70%; however, survival for patients suffering from metastatic disease remain disappointing with only 20% of individuals being alive past 5 years post-diagnosis.

View Article and Find Full Text PDF

Purpose: As immune checkpoint inhibitors continue to acquire new indications, it is important to understand the impact their use has on patients. This study adds to current literature by presenting an analysis of hospitalizations in this population. The primary objective was to assess the reasons for an emergency department visit or hospital admission in patients who receive immune checkpoint inhibitors.

View Article and Find Full Text PDF